Donate Help Contact The AHA Sign In Home
American Heart Association
Hypertension
Search: search_blue_button Advanced Search
Hypertension. 2008;52:301-307
Published online before print June 30, 2008, doi: 10.1161/HYPERTENSIONAHA.107.105551
This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Data Supplement
Right arrow All Versions of this Article:
52/2/301    most recent
HYPERTENSIONAHA.107.105551v1
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow Request Permissions
Citing Articles
Right arrow Citing Articles via HighWire
Google Scholar
Right arrow Articles by Monassier, L.
Right arrow Articles by de Champlain, J.
PubMed
Right arrow PubMed Citation
Right arrow Articles by Monassier, L.
Right arrow Articles by de Champlain, J.
Right arrowPubmed/NCBI databases
*Compound via MeSH
*Substance via MeSH
Related Collections
Right arrow Cardiovascular Pharmacology
Right arrow Animal models of human disease
Right arrow Hypertension - basic studies
Right arrow Hypertrophy
Right arrow Oxidant stress
Right arrow Receptor pharmacology

(Hypertension. 2008;52:301.)
© 2008 American Heart Association, Inc.


Original Articles

Serotonin 5-HT2B Receptor Blockade Prevents Reactive Oxygen Species–Induced Cardiac Hypertrophy in Mice

Laurent Monassier; Marc-André Laplante; Fabrice Jaffré; Pascal Bousquet; Luc Maroteaux; Jacques de Champlain

From the Laboratoire de Neurobiologie et Pharmacologie Cardiovasculaire (L. Monassier, P.B.), INSERM, U-715, Faculté de Médecine, Strasbourg, France; Département de Physiologie (M-A.L., J.d.C.), Faculté de Médecine, Université de Montréal and Laboratoire de Recherche sur le Système Nerveux Autonome, Institut de Recherche Clinique, Montréal, Quebec, Canada; and INSERM (F.J., L. Maroteaux), U-389, Université Pierre et Marie Curie, Institut du Fer à Moulin, Paris, France.

Correspondence to Laurent Monassier, INSERM U-715, Faculté de Médecine, 11 rue Humann, Strasbourg, France. E-mail laurent.monassier{at}medecine.u-strasbg.fr

We established previously that 5-HT2B receptors are involved in cardiac hypertrophy through the regulation of hypertrophic cytokines in cardiac fibroblasts. Moreover, the generation of reactive oxygen species and tumor necrosis factor-{alpha} through the activation of reduced nicotinamide-adenine dinucleotide phosphate [NAD(P)H] oxidase has been implicated in cardiac hypertrophy. In this study, we investigated whether 5-HT2B receptors could be involved in the development of cardiac hypertrophy associated with superoxide anion production. Therefore, we measured the effects of serotonergic 5-HT2B receptor blockade on left-ventricular superoxide anion generation in 2 established pharmacological models of cardiac hypertrophy, ie, angiotensin II and isoproterenol infusions in mice. Angiotensin II infusion for 14 days increased superoxide anion concentration (+32%), NAD(P)H oxidase maximal activity (+84%), and p47phox NAD(P)H oxidase subunit expression in the left ventricle together with hypertension (+37 mm Hg) and cardiac hypertrophy (+17% for heart weight:body weight). The 5-HT2B receptor blockade by a selective antagonist (SB215505) prevented the increase in cardiac superoxide generation and hypertrophy. Similarly, infusion for 5 days of isoproterenol increased left-ventricular NAD(P)H oxidase activity (+48%) and cardiac hypertrophy (+31%) that were prevented by the 5-HT2B receptor blockade. Finally, in the primary culture of left-ventricular cardiac fibroblasts, angiotensin II and isoproterenol stimulated NAD(P)H oxidase activity. This activation was prevented by SB215505. These findings suggest that the 5-HT2B receptor may represent a new target to reduce cardiac hypertrophy and oxidative stress. Its blockade affects both angiotensin II and β-adrenergic trophic responses without significant hemodynamic alteration.


Key Words: 5-HT2B • NAD(P)H oxidase • superoxide anion • angiotensin • adrenergic • cardiac • hypertrophy




This article has been cited by other articles:


Home page
Circ. Res.Home page
K.-G. Shyu
Serotonin 5-HT2B Receptor in Cardiac Fibroblast Contributes to Cardiac Hypertrophy: A New Therapeutic Target for Heart Failure?
Circ. Res., January 2, 2009; 104(1): 1 - 3.
[Full Text] [PDF]


Home page
Circ. Res.Home page
F. Jaffre, P. Bonnin, J. Callebert, H. Debbabi, V. Setola, S. Doly, L. Monassier, B. Mettauer, B. C. Blaxall, J.-M. Launay, et al.
Serotonin and Angiotensin Receptors in Cardiac Fibroblasts Coregulate Adrenergic-Dependent Cardiac Hypertrophy
Circ. Res., January 2, 2009; 104(1): 113 - 123.
[Abstract] [Full Text] [PDF]